Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Index
-
Market Cap
264.69M
Enterprise Value
292.12M
Income
-59.52M
Sales
205.31M
Book/sh
1.04
Cash/sh
0.70
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
450
IPO
Apr 23, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
1.29
P/B
3.92
P/C
5.80
P/FCF
-
EV/EBITDA
-
EV/Sales
1.42
Quick Ratio
1.95
Current Ratio
2.90
Debt/Eq
1.08
LT Debt/Eq
1.02
Option/Short
Yes / Yes
EPS (ttm)
-0.93
EPS next Y
-0.77
EPS next Q
-0.25
EPS this Y
8.60%
EPS next Y
8.94%
EPS next 5Y
9.18%
EPS past 3/5Y
-6.38% -61.76%
Sales past 3/5Y
14.46% 29.96%
EPS Y/Y TTM
-17.90%
Sales Y/Y TTM
-3.95%
EPS Q/Q
11.63%
Sales Q/Q
-4.24%
Insider Own
26.71%
Insider Trans
2.52%
Inst Own
49.01%
Inst Trans
-9.79%
ROA
-30.72%
ROE
-71.99%
ROIC
-43.48%
Gross Margin
79.45%
Oper. Margin
-26.17%
Profit Margin
-28.99%
SMA20
-3.31%
SMA50
-8.34%
SMA200
28.47%
Trades
Shs Outstand
65.24M
Shs Float
47.67M
52W High
7.08 -42.51%
52W Low
1.17 247.86%
Volatility
4.79% 5.33%
ATR (14)
0.22
RSI (14)
44.72
Beta
1.60
Rel Volume
0.00
Avg Volume
294.77K
Volume
0
Perf Week
-0.73%
Perf Month
-9.15%
Perf Quarter
2.52%
Perf Half Y
122.40%
Perf YTD
66.12%
Perf Year
-40.15%
Perf 3Y
-58.93%
Perf 5Y
-83.35%
Perf 10Y
-
Prev Close
4.07
Price
4.07
Change %
0.00%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Treace John T.Chief Executive OfficerAug 20 '26Buy4.4439,944177,1767,388,383Aug 24 05:00 PM
Treace John T.Chief Executive OfficerAug 24 '26Buy4.3411,00047,7317,404,383Aug 24 05:00 PM
Treace John T.Chief Executive OfficerAug 21 '26Buy4.355,00021,7487,393,383Aug 24 05:00 PM
Treace John T.Chief Executive OfficerJun 10 '26Buy4.0229,430118,4267,353,263Jun 11 04:52 PM
Treace John T.Chief Executive OfficerJun 11 '26Buy4.0422,88792,5417,376,150Jun 11 04:52 PM
Treace John T.Chief Executive OfficerJun 01 '26Buy3.5650,000177,9157,323,833Jun 01 04:38 PM
Treace John T.Chief Executive OfficerMay 28 '26Buy3.0261,202184,8247,273,833May 28 04:33 PM
Treace John T.Chief Executive OfficerMay 27 '26Buy2.8749,810143,1897,212,631May 28 04:33 PM
Treace John T.Chief Executive OfficerMay 26 '26Buy2.794,50812,5767,162,821May 28 04:33 PM
Treace John T.Chief Executive OfficerMay 14 '26Buy2.6261,750161,4957,158,313May 14 05:33 PM
Treace John T.Chief Executive OfficerMay 13 '26Buy2.4649,013120,5337,096,563May 14 05:33 PM
Treace John T.Chief Executive OfficerMay 12 '26Buy2.1743,00093,4787,047,550May 14 05:33 PM
Scanlan Sean F.Chief Innovation OfficerFeb 10 '26Option Exercise1.0516,87517,719706,474Feb 11 09:00 PM
Scanlan Sean F.Chief Innovation OfficerJan 21 '26Option Exercise0.7253,50038,520427,099Jan 23 09:30 PM
Treace Medical Concepts, Inc. engages in the designing, manufacturing, and marketing of orthopedic medical devices and biologic solutions. The firm offers Lapiplasty, a bunion surgery for three-dimensional bunion correction. It operates and distributes its products and services under the following trademarks: Treace Medical Concepts, Lapiplasty, Fast Grafter, Align My Toe, The Future of Hallux Valgus, Fix It Right The First Time, and Plantar Python. The company was founded by John T. Treace in July 2013 and is headquartered in Ponte Vedra Beach, FL.
FounderMr. John T. Treace
Chief Financial OfficerMr. Mark L. Hair CPA
Chief Legal & Compliance Officer and Corporate SecretaryMr. Scot M. Elder J.D.
Chief Innovation & Marketing OfficerDr. Sean F. Scanlan Ph.D.
Chief Operations & Supply Chain OfficerMr. Terry W. Lubben